Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for infants and babies.

The votes in favor of Merck's shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom are well-known vaccine critics.